{"id":1984,"date":"2023-04-16T20:52:00","date_gmt":"2023-04-16T20:52:00","guid":{"rendered":"https:\/\/survivingdiabetes.com\/?p=1984"},"modified":"2022-10-09T21:06:01","modified_gmt":"2022-10-09T21:06:01","slug":"780g-medtronic-results-from-european-and-chilean-users","status":"publish","type":"post","link":"https:\/\/survivingdiabetes.com\/780g-medtronic-results-from-european-and-chilean-users\/","title":{"rendered":"780g Medtronic – Results From European and Chilean Users"},"content":{"rendered":"\n
This article explores the results of 780g medtronic use by European and Chilean patients. It also looks at differences in glycemic control between in-clinic and remote initiation programs and the costs of initiation programs. Although Medtronic is not the AID leader yet, it is quickly catching up.<\/p>\n\n\n\n
Results from European and Chilean users of 780g medtronic<\/h2>\n\n\n